Vaccine Journal

Overview

publication venue for

• Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting. 2024
• Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy. 2024
• Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient. 2024
• Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic. 2024
• COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic. 2024
• Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes..  41. 2023
• Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17..  41. 2023
• Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses. 2022
• Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial. 2022
• Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana..  40. 2022
• Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial. 2022
• Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models..  39. 2021
• Variable immunogenicity of a vivax malaria blood-stage vaccine candidate..  39. 2021
• Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice..  38. 2020
• Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status..  38. 2020
• Impact of media reports regarding influenza vaccine on obstetricians' vaccination practices..  38. 2020
• Beliefs in vaccine as causes of autism among SPARK cohort caregivers..  38. 2020
• Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes..  38. 2019
• Development and acceptability of a video-based vaccine promotion tutorial for obstetric care providers..  37. 2019
• Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men..  37. 2019
• Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines..  36. 2018
• In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection..  36. 2018
• A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats..  36. 2018
• Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice..  36. 2018
• Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection..  35. 2017
• Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now..  35. 2017
• Maternal Tdap vaccination and risk of infant morbidity..  35. 2017
• Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination..  35. 2017
• Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection..  34. 2016
• Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine..  34. 2016
• Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013..  34. 2016
• Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City..  33. 2015
• Increasing influenza vaccination in New York City taxi drivers: A community driven approach..  33. 2015
• Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection..  32. 2014
• Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events..  32. 2014
• Identifying human papillomavirus vaccination practices among primary care providers of minority, low-income and immigrant patient populations..  32. 2014
• Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs..  32. 2014
• A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer..  31. 2012
• Opportunities and challenges of Web 2.0 for vaccination decisions..  30. 2012
• Development of a DNA vaccine targeting Merkel cell polyomavirus.  30:1322-1329. 2012
• Development of a DNA vaccine targeting Merkel cell polyomavirus.  30:1322-1329. 2012
• LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines.  30:784-793. 2012
• Development of a DNA vaccine targeting Merkel cell polyomavirus..  30. 2011
• Risk perception and communication in vaccination decisions: a fuzzy-trace theory approach..  30. 2011
• LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines..  30. 2011
• Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection..  29. 2011
• Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies..  29 Suppl 2. 2011
• Willingness of pregnant women to vaccinate themselves and their newborns with the HPV vaccine..  29. 2011
• Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice..  29. 2011
• Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF..  29. 2011
• Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development..  28. 2010
• Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease..  28. 2010
• Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii..  28. 2010
• Echinacea purpurea aerial extract alters course of influenza infection in mice..  28. 2010
• Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1..  27. 2009
• Development of effective vaccines for old mice in a tumor model..  27. 2008
• Evaluation of widely consumed botanicals as immunological adjuvants..  26. 2008
• CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals..  26. 2008
• Apnea and its possible relationship to immunization in ex-premature infants..  26. 2008
• Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies..  25. 2007
• Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes..  25. 2007
• Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies..  25. 2007
• Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center..  24. 2005
• A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21..  23. 2005
• A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside..  22. 2004
• CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems..  22. 2004
• The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine..  21. 2003
• Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice..  21. 2003
• The role of lipopolysaccharide in T-cell responses following DNA vaccination..  21. 2003
• Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies..  20. 2002
• Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependent antigen administrations on HIV-1 progression. Italian Register for HIV infection in children..  18. 2000
• CTL induction using synthetic peptides delivered in emulsions--critical role of the formulation procedure..  15. 1997
• Cytotoxic T cell induction with ratchet peptide libraries..  14. 1996
• Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity..  14. 1996
• Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides..  14. 1996
• Relation of chronic disease and immune response to influenza vaccine in the elderly..  7. 1989
• Response to Donahue et al. 2017 in press article..  36. 2018
• Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002. 2003
• So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development. 2020
• Chorioamnionitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. 2019
• Rising rates of vaccine exemptions: problems with current policy and more promising remedies. 2014

Identity

ISO Abbreviation

• Vaccine

Linking ISSN

• 0264-410X

International Standard Serial Number (ISSN)

• 0264-410X

Electronic International Standard Serial Number (EISSN)

• 1873-2518